Maternal and Neonatal Hemostasis
Gili Kenet,Benjamin Brenner
DOI: https://doi.org/10.1055/s-0042-1760331
2023-01-18
Seminars in Thrombosis and Hemostasis
Abstract:Hemostasis is a dynamic process that begins at early stages of fetal development. The hemostatic system comprises procoagulant, natural anticoagulant, and fibrinolytic proteins that interact with each other, as well as with the endothelial wall and blood cells in a complex, yet balanced manner, aiming to avoid either bleeding or thrombosis. Pregnancy is a unique physiological state in which natural biologic alterations predispose both mothers and their offspring to higher risk of hypercoagulability and bleeding. This special issue of Seminars in Thrombosis and Hemostasis is dedicated to maternal and neonatal hemostasis. In the article entitled "Hemostasis in the pregnant women, the placenta, the fetus and the newborn infant," Warren et al[1] address increased maternal thrombotic risk, caused, in part, by elevation of von Willebrand factor (VWF), factor VIII (FVIII) and fibrinogen, activated protein C resistance, reduction of free protein S, and decreased fibrinolysis. The placental vascular surface is of trophoblastic origin, and yet exhibits high expression of tissue factor. The fetal hemostatic system has a decreased capacity to generate or regulate thrombin. The authors suggest that dysfunction of the maternal/ placental/fetal unit gives rise to gestational complications, including preeclampsia, fetal growth restriction, placental abruption, and premature delivery. Thrombotic events may occur even prior to pregnancy, during ovulation or following assisted reproductive techniques (ARTs). As the number of women utilizing ART to conceive is steadily increasing, while solid data regarding the optimal management are scarce, Grandone et al[2] discuss the ART of thromboprophylaxis in this setting. The authors focus on general risk factors for venous thromboembolism in these women (age, body mass index, thrombophilia, and immobilization) as well as ART-specific conditions (polycystic ovary syndrome, ovarian hyperstimulation syndrome) and attempt to provide suggestions and some guidance to be applied in clinical practice. Women with hereditary or acquired thrombophilia are at a particularly high risk of thrombosis and pregnancy-related complications. Gris et al[3] describe how antiphospholipid antibodies (APLAs) may affect maternal and neonatal outcomes. APLAs have long been known to be associated with the occurrence of certain pregnancy-related complications and therefore antithrombotic-based prophylaxis has become the standard of care, improving maternal morbidity and prognosis. Late pregnancy placental diseases still occur. Some APLA-positive mothers are predisposed to develop neuropsychiatric disorders or even cancer, and a concern is raised regarding the neurodevelopment of children born following such pregnancies. Hence, the systemic impact of APLA should be further investigated, as suggested by authors. Certain comorbidities may increase the risk of thrombosis in pregnant women. Among these, hematological malignancies, hemolytic anemia, and human immunodeficiency virus (HIV) deserve special attention. Both cancer and thrombosis induce a procoagulant environment that may lead to maternal and fetal complications. As the incidence of hematological malignancies diagnosed during pregnancy is rising, the management of thrombosis during pregnancy poses specific challenges. Krayem et al[4] present a case-based review regarding the complex issue of thrombotic risk assessment and management in pregnant women with myeloproliferative neoplasms, lymphoma, and leukemia. Schapkaitz et al[5] address HIV infection, promoting inflammation and endothelial dysfunction, as well as the prothrombotic risks associated with antiretroviral therapy during gestation. Among the research priorities mentioned by authors is generation of HIV-specific thromboprophylaxis recommendations that should be agreed upon by a multidisciplinary team managing these women. Papadakis and Brenner[6] highlight the latest advances in diagnosis and management of women with hemolytic anemia during pregnancy, as hemolytic anemias frequently occur at the reproductive age. While a link between hemolysis and hypercoagulability has previously been suggested, the extent of thrombotic risk in pregnant women with hemolytic anemia remains debatable. This review is of importance due to the paucity of data regarding its topic. The article by Malinowski and Abdul-Kadir[7] addresses the issues of bleeding during pregnancy and around delivery in women with inherited rare bleeding disorders (RBDs). Obstetric challenges may sometimes unmask the presence of a previously unknown bleeding disorder, and certainly among women with a known inherited RBD, gestation, labor, and puerperium may be adversely influenced. The article delineates the clinical approach to the management of pregnancy and delivery in the presence of RBD and emphasizes the importance of a multidisciplinary team in this setting. The rol -Abstract Truncated-
peripheral vascular disease,hematology